Supplemental Digital Content 1. Hepatotoxicity related to ICPI administration when compared to patients without hepatotoxicity and patients experienced grade III-IV hepatotoxicity
Characteristics
No. (%) Hepatotoxicity, No. (%)
P (n=90) Absence Grade III-IV
(n=69) (n=21)
Sex 0.090
Female 31(34.4) 27(39.1) 4(19.0) Male 59(65.6) 42(60.9) 17(81.0)
Age, years 0.145
<65 39(43.3) 27(39.1) 12(57.1)
≥65 51(56.7) 42(60.9) 9(42.9)
BW, kg 0.894
< 60 46(51.1) 35(50.7) 11(52.4)
≥60 44(48.9) 34(49.3) 10(47.6)
BSA, m2 0.320
<1.6 34(37.8) 28(40.6) 6(28.6)
≥1.6 56(62.2) 41(59.4) 15(71.4)
ECOG PSa 0.365
0-1 69(88.5) 52(86.7) 17(94.4)
2-4 9(11.5) 8(13.3) 1(5.6)
CVD or DM 0.326
Yes 4347.8) 31(44.9) 12(57.1)
No 47(52.2) 38(55.1) 9(42.9)
Liver metastasis 0.379
Yes 12(13.3) 8(11.6) 4(19.0)
No 78(86.7) 61(88.4) 17(81.0)
Underlying liver disease 0.936
Yes 4(4.4) 3(4.3) 1(4.8)
No 86(95.6) 66(95.7) 20(95.2)
PD-L1 expressionb 0.898
Yes 44(74.6) 33(75.0) 11(73.3)
No 15(25.4) 11(25.0) 4(26.7)
Interval from
previous chemotherapyc (days)
0.957
<30 28(38.4) 21(38.2) 7(38.9)
≥30 45(61.6) 34(61.8) 11(61.1)
Cancer type 0.231
Lung 53(58.9) 43(62.3) 10(47.6)
§Others 37(41.1) 26(37.7) 11(52.4)
Anticancer drugs 0.259
Yes 4(4.4) 4(5.8) 0(0)
No 86(95.6) 65(94.2) 21(100.0)
Acetaminophen 0.290
Yes 30(33.3) 21(30.4) 9(42.9)
No 60(66.7) 48(69.6) 12(57.1)
HMG-CoA reductase inhibitors
0.114
Yes 9(10.0) 5(7.2) 4(19.0)
No 81(90.0) 64(92.8) 17(81.0)
Antihypertensives 0.938
Yes 22(24.4) 17(24.6) 5(23.8)
No 68(75.6) 52(75.4) 16(76.2)
H2 blockers 0.717
Yes 23(25.6) 17(24.6) 6(28.6)
No 67(74.4) 52(75.4) 15(71.4)
PPIs 0.518
Yes 31(34.4) 25(36.2) 6(28.6)
No 59(65.6) 44(63.8) 15(71.4)
Hepatotonic agents 0.738
Yes 15(16.7) 11(15.9) 4(19.0)
No 75(83.3) 58(84.1) 17(81.0)
BSA, body surface area; BW, body weight; CVD, cardiovascular disease; DM, diabetes mellitus, ECOG PS, Eastern Cooperative Oncology Group Performance Scale; PD-L1, programmed cell death ligand-1; PPI, proton pump inhibitor
§Other cancer types were gastric cancer (n=18), melanoma (n=11), bladder cancer (n=7), kidney cancer (n=7), colorectal cancer (n=6), biliary tract cancer (n=4), esophageal cancer (n=4), ovarian cancer (n=3), thymoma (n=3), ureteral cancer (n=3), lymphoma (n=2), breast cancer (n=2), oral cancer (n=2), head and neck cancer (n=1), pancreatic cancer (n=1), and vulvar cancer (n=1).
aThere were 12 missing data for ECOG PS.
bThere were 31 missing data for PD-L1 expression.
cThere were 17 missing data for interval from previous chemotherapy.
